<?xml version="1.0" encoding="UTF-8"?>
<p>We evaluated TMR-001, a proprietary bulk drug substance solution of ranpirnase, an RNase A enzyme, extracted from oocytes of Northern leopard frogs 
 <italic>Lithobates pipiens</italic>, formerly 
 <italic>Rana pipiens</italic> [
 <xref rid="B7-viruses-12-00177" ref-type="bibr">7</xref>]. Other forms of the drug were developed under the names Pannon, P-30, and Onconase for Injection (TMR-004) as an antitumor agent [
 <xref rid="B8-viruses-12-00177" ref-type="bibr">8</xref>,
 <xref rid="B9-viruses-12-00177" ref-type="bibr">9</xref>]. Based on studies showing selective cytotoxicity in transformed cells [
 <xref rid="B10-viruses-12-00177" ref-type="bibr">10</xref>], TMR-004, manufactured by Alfacell Inc., was advanced to phase III clinical trials for mesothelioma treatment [
 <xref rid="B11-viruses-12-00177" ref-type="bibr">11</xref>,
 <xref rid="B12-viruses-12-00177" ref-type="bibr">12</xref>]. In these trials the drug was administered to more than one thousand patients [
 <xref rid="B13-viruses-12-00177" ref-type="bibr">13</xref>]. It was found to have low immunogenicity and was well-tolerated with few side effects [
 <xref rid="B14-viruses-12-00177" ref-type="bibr">14</xref>]. 
</p>
